摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

spiro[3.3]heptane-2,6-dicarbonyl chloride | 60334-24-9

中文名称
——
中文别名
——
英文名称
spiro[3.3]heptane-2,6-dicarbonyl chloride
英文别名
spiro[3.3]heptane-2,6-dicarbonyl dichloride;Spiro<3.3>heptan-dicarbonsaeure-(2,6)-dichlorid;Spiro<3.3>heptan-dicarbonsaeure-2,5-dichlorid;Spiro[3.3]heptan-2,6-dicarbonylchlorid
spiro[3.3]heptane-2,6-dicarbonyl chloride化学式
CAS
60334-24-9
化学式
C9H10Cl2O2
mdl
——
分子量
221.083
InChiKey
DKOZSQUGSDMGHI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.78
  • 拓扑面积:
    34.1
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • Enantiopure Spiro[3.3]heptane-2,6-dicarboxylic Acid
    作者:Hong-Zhi Tang、Hiroshi Miura、Yusuke Kawakami
    DOI:10.1080/10242430210705
    日期:2002.1
    Using chiral HPLC and 13C NMR analyses, the optical purity of (+)-spiro[3.3]heptane-2,6-dicarboxylic acid (1) obtained by the known diastereomer method with brucine was first clarified to be 90% e.e., which was conventionally considered to be 100% e.e. Among the ester derivatives synthesized, dicinnamyl spiro[3.3]heptane-2,6-dicarboxylate (2) was found to show high optical separation ability on the
    使用手性HPLC和13C NMR分析,首先将通过已知的非对映异构体方法与brucine获得的(+)-螺[3.3]庚烷-2,6-二羧酸(1)的光学纯度明确为90%ee,其为传统上被认为是100%ee在合成的酯衍生物中,发现二肉桂基螺[3.3]庚烷-2,6-二羧酸酯(2)在手性HPLC上具有苯甲酸纤维素苯酯固定相洗脱的高光学分离能力,用己烷/ 2-丙醇(10/1,v / v)在35摄氏度下的流速为0.4 ml / min(分离系数,a,1.14),分离出的旋光纯正(+)-和(-)-2 αD26分别为+1.84度(c = 1.74,CHCl 3)和-1.84度(c = 1.74,CHCl 3)。光学解的(+)-/(-)-2的酸性解,没有消旋作用,产生了光学纯化的(+)-/(-)-1,
  • Benzamide imidazopyrazine Btk inhibitors
    申请人:MERCK SHARP & DOHME CORP.
    公开号:US10087188B2
    公开(公告)日:2018-10-02
    The present invention provides Bruton's Tyrosine Kinase (Btk) inhibitor compounds according to Formula (I), or pharmaceutically acceptable salts thereof, or to pharmaceutical compositions comprising these compounds and to their use in therapy. In particular, the present invention relates to the use of Btk inhibitor compounds of Formula (I) in the treatment of Btk mediated disorders.
    本发明提供了根据式(I)的布鲁顿酪氨酸激酶(Btk)抑制剂化合物或其药学上可接受的盐,或包含这些化合物的药物组合物及其在治疗中的用途。特别是,本发明涉及式(I)的 Btk 抑制剂化合物在治疗 Btk 介导的疾病中的用途。
  • Synthesis of Conformationally Constrained Diaminodicarboxylic Acid Derivatives
    作者:Robin A. Weatherhead、Michael D. Carducci、Eugene A. Mash
    DOI:10.1021/jo901892d
    日期:2009.11.20
    Functionally protected forms of three conformationally constrained diaminodicarboxylic acids were synthesized and characterized. 2,2'-Diaminospiro[3.3]heptane-2,2'-dicarboxylic acid, an analogue of diaminopimelic acid, was prepared in racemic form and the structure established by X-ray crystallographic analysis of the methyl ester hydrochloride. trans-1,4-Diaminocyclohexane-1,4-dicarboxylic acid was prepared and its structure established by X-ray crystallographic analysis of the corresponding Cbz-protected ethyl ester. cis- and trans-2,6-diamino-1,2,3,5,6,7-hexahydro-s-indacene-2,6-dicarboxylic acids were synthesized and the structures assigned by X-ray crystallographic analysis of the corresponding Boc-protected ethyl ester and Cbz-protected ethyl ester, respectively.
  • Gore,J. et al., Bulletin de la Societe Chimique de France, 1968, p. 2432 - 2437
    作者:Gore,J. et al.
    DOI:——
    日期:——
  • Backer; Kemper, Recueil des Travaux Chimiques des Pays-Bas, 1938, vol. 57, p. 1249,1252
    作者:Backer、Kemper
    DOI:——
    日期:——
查看更多